Nath Bio-Genes (India) Statistics

Total Valuation

Nath Bio-Genes (India) has a market cap or net worth of INR 3.55 billion. The enterprise value is 4.80 billion.

Market Cap	3.55B
Enterprise Value	4.80B

Important Dates

The next estimated earnings date is Wednesday, January 22, 2025.

Earnings Date	Jan 22, 2025
Ex-Dividend Date	Aug 9, 2024

Share Statistics

Nath Bio-Genes (India) has 19.00 million shares outstanding. The number of shares has decreased by -0.20% in one year.

Current Share Class	n/a
Shares Outstanding	19.00M
Shares Change (YoY)	-0.20%
Shares Change (QoQ)	+10.15%
Owned by Insiders (%)	7.33%
Owned by Institutions (%)	4.36%
Float	6.77M

Valuation Ratios

The trailing PE ratio is 9.05.

PE Ratio	9.05
Forward PE	n/a
PS Ratio	1.01
PB Ratio	0.61
P/TBV Ratio	0.56
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.69, with an EV/FCF ratio of -26.30.

EV / Earnings	12.20
EV / Sales	1.37
EV / EBITDA	9.69
EV / EBIT	10.40
EV / FCF	-26.30

Financial Position

The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.20.

Current Ratio	2.84
Quick Ratio	0.85
Debt / Equity	0.20
Debt / EBITDA	2.57
Debt / FCF	-6.98
Interest Coverage	5.34

Financial Efficiency

Return on equity (ROE) is 6.33% and return on invested capital (ROIC) is 3.89%.

Return on Equity (ROE)	6.33%
Return on Assets (ROA)	3.45%
Return on Capital (ROIC)	3.89%
Revenue Per Employee	8.30M
Profits Per Employee	930,809
Employee Count	423
Asset Turnover	0.42
Inventory Turnover	0.56

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.90% in the last 52 weeks. The beta is 1.33, so Nath Bio-Genes (India)'s price volatility has been higher than the market average.

Beta (5Y)	1.33
52-Week Price Change	-11.90%
50-Day Moving Average	191.75
200-Day Moving Average	205.75
Relative Strength Index (RSI)	38.71
Average Volume (20 Days)	22,960

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Nath Bio-Genes (India) had revenue of INR 3.51 billion and earned 393.73 million in profits. Earnings per share was 20.64.

Revenue	3.51B
Gross Profit	2.59B
Operating Income	461.77M
Pretax Income	410.05M
Net Income	393.73M
EBITDA	495.59M
EBIT	461.77M
Earnings Per Share (EPS)	20.64

Full Income Statement

Balance Sheet

The company has 20.77 million in cash and 1.27 billion in debt, giving a net cash position of -1.25 billion or -66.00 per share.

Cash & Cash Equivalents	20.77M
Total Debt	1.27B
Net Cash	-1.25B
Net Cash Per Share	-66.00
Equity (Book Value)	6.40B
Book Value Per Share	304.81
Working Capital	3.34B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 112.45 million and capital expenditures -295.08 million, giving a free cash flow of -182.63 million.

Operating Cash Flow	112.45M
Capital Expenditures	-295.08M
Free Cash Flow	-182.63M
FCF Per Share	-9.61

Full Cash Flow Statement

Margins

Gross margin is 73.70%, with operating and profit margins of 13.16% and 11.22%.

Gross Margin	73.70%
Operating Margin	13.16%
Pretax Margin	11.68%
Profit Margin	11.22%
EBITDA Margin	14.12%
EBIT Margin	13.16%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 1.08%.

Dividend Per Share	2.00
Dividend Yield	1.08%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	9.86%
Buyback Yield	0.20%
Shareholder Yield	1.28%
Earnings Yield	11.05%
FCF Yield	-5.15%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a